Vishnu Priya Pulipati: The Endocrinologist’s Role in Lp(a) and Cardiovascular Risk Reduction
Vishnu Priya Pulipati, Founder and Host of LipidCurious Podcast, Member of Institutional Review Ethics Board at Saint Francis Health System, shared a post on LinkedIn about a recent article by Scott Buzby et. al, published in Healio, adding:
“Excited to share the September 2026 cover story from Healio Endocrine Today on Lp(a) and cardiovascular risk: What endocrinologists should know.
As our understanding of Lp(a) continues to evolve, Endocrinologists and physicians across specialties passionate about cardiometabolic prevention play an important role in recognizing elevated Lp(a), identifying individuals and families at increased cardiovascular risk, and incorporating it into a broader approach to cardiovascular risk reduction.
I was grateful for the opportunity to contribute to this discussion and share perspectives on how we can translate the growing science around Lp(a) into clinical practice.”
Title: Lp(a) and cardiovascular risk: What endocrinologists should know
Authors: Scott Buzby, Erik Swain, Richard Smith

Stay updated with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis